Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.0%

3 terminated/withdrawn out of 30 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

33%

4 of 12 completed trials have results

Key Signals

5 recruiting4 with results

Enrollment Performance

Analytics

N/A

17(81.0%)

Phase 3

2(9.5%)

Phase 4

1(4.8%)

Phase 2

1(4.8%)

21Total

N/A(17)

Phase 3(2)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials

NCT06455787Not ApplicableRecruiting

J-Valve Transfemoral Pivotal Study

Role: collaborator

NCT07543874Not Yet Recruiting

MITRAClip GENeration 5 Mitral Valve Transcatheter Edge-to-Edge Repair Registry

Role: collaborator

NCT04592445Not ApplicableRecruiting

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Role: collaborator

NCT05893498Not ApplicableActive Not Recruiting

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

Role: collaborator

NCT06568003Not ApplicableActive Not Recruiting

TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)

Role: collaborator

NCT05521542Not ApplicableActive Not Recruiting

Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease

Role: collaborator

NCT06271590Not ApplicableRecruiting

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

Role: collaborator

NCT07062471Not ApplicableNot Yet Recruiting

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

Role: collaborator

NCT05908331Not ApplicableRecruiting

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

Role: collaborator

NCT05357404Active Not Recruiting

Age and Sex-Specific PREValence of AcqUirEd VALVular Heart DiseasE

Role: lead

NCT06368401Not ApplicableActive Not Recruiting

A First in Human Study for the Versa Device for Tricuspid Regurgitation

Role: collaborator

NCT02661451Not ApplicableActive Not Recruiting

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Role: lead

NCT04100720Not ApplicableWithdrawn

Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation

Role: collaborator

NCT03813524Not ApplicableTerminated

Cardiovalve Transfemoral Mitral Valve System

Role: collaborator

NCT04912323Not ApplicableRecruiting

Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease

Role: collaborator

NCT05949515Completed

Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility

Role: lead

NCT05077657Completed

Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System

Role: collaborator

NCT03702244Not ApplicableCompleted

The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization

Role: collaborator

NCT03521804Not ApplicableTerminated

Safety and Efficacy Study of the SoundBite™ Crossing System With ACTIVE Wire in Coronary CTOs.

Role: collaborator

NCT03108456Not ApplicableUnknown

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

Role: collaborator